

## Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences

November 6, 2017

WATERTOWN, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- [Tetraphase Pharmaceuticals, Inc.](#) (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will present at the following upcoming investor conferences:

- Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017 at 8:00 a.m. Eastern Time at the Lotte New York Palace Hotel in New York City
- PiperJaffray 29th Annual Healthcare Conference on Wednesday, November 29, 2017 at 9:30 a.m. Eastern Time at the Lotte New York Palace Hotel in New York City

Live audio webcasts of the presentations will be available on the company's website at <http://ir.tphase.com/events.cfm>. Archived presentations will be available for 30 days.

### About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit [www.tphase.com](http://www.tphase.com) for more company information.

### Investor Contacts:

Tetraphase Pharmaceuticals  
Teri Dahlman  
617-600-7040  
[tdahlman@tphase.com](mailto:tdahlman@tphase.com)

Argot Partners  
Maeve Conneighton  
206-899-4940  
[maeve@argotpartners.com](mailto:maeve@argotpartners.com)

### Media Contact:

Sam Brown Inc.  
Mike Beyer  
312-961-2502  
[mikebeyer@sambrown.com](mailto:mikebeyer@sambrown.com)

Source: Tetraphase Pharmaceuticals, Inc.